Methods | Six-week randomised, double-blind study. | |
Participants | Outpatients fulfilling DSM-III criteria for major depression, with a score between 18 and 25 on the HDRS-21. Age range: 18-65 years old. Exclusion criteria: organic brain disease, seizures, other serious illness, hyperthyrodism, allergy, drug or alcohol abuse, use of MAOI within 2 week, serious suicidal risk, pregancy and lactation |
|
Interventions | Fluoxetine: 31 participants. Amineptine: 32 participants. Fluoxetine dose: 20 mg/day. Amineptine dose: 200 mg/day. |
|
Outcomes | Hamilton Rating Scale for Depression (HDRS-21), Montgomery and Asberg Scale for Depression (MADRS), CGI for Severity | |
Notes | Funding: unclear | |
Risk of bias | ||
Item | Authors’ judgement | Description |
Allocation concealment? | Unclear | B - Unclear |